Glutathione peroxidase activity in the blood cells of psoriatic patients correlates with their responsiveness to Efalizumab

Free Radical Research

Volumn 45, Issue 5, 2011, Pages 585-599

  Pastore, Saveria ^a   Mariani, Valentina ^a   Lulli, Daniela ^a   Gubinelli, Emanuela ^a   Raskovic, Desanka ^a   Mariani, Serena ^a   Stancato, Andrea ^a   De Luca, Chiara ^a   Pecorelli, Alessandra ^b   Valacchi, Giuseppe ^b,c   Potapovich, Alla I ^a,d   Kostyuk, Vladimir A ^a,d   Korkina, Liudmila G ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c Kyung Hee University   (South Korea)

^d BELARUSIAN STATE UNIVERSITY   (Belarus)

Author keywords

Catalase; cytokines; Efalizumab; glutathione peroxidase; glutathione S transferase; MDA; psoriasis; PUFAs

Indexed keywords

EFALIZUMAB; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; POLYUNSATURATED FATTY ACID;

ADULT; ARTICLE; BLOOD CELL; CELL FUNCTION; CELL MEMBRANE; CLINICAL ARTICLE; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; OXIDATIVE STRESS; PSORIASIS; RELAPSE; REMISSION; T LYMPHOCYTE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; BLOOD CELLS; CATALASE; CYTOKINES; ERYTHROCYTES; FATTY ACIDS, UNSATURATED; FEMALE; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; HUMANS; MALE; MALONDIALDEHYDE; MIDDLE AGED; MONOCYTES; PSORIASIS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 79952677366     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.3109/10715762.2011.560150     Document Type: Article

References (50)

1. Nestle FO, Kaplan DH, Barker J. Psoriasis. New Engl J Med 2009;361:496-509.
2. Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS, Bowman EP, Krueger JG. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008;128:1207-1211. (Pubitemid 351543220)
3. Girolomoni G, Gisondi P. Psoriasis and metabolic comorbidities: the importance of well-designed prospective studies. Dermatology 2008;217:222-224.
4. Gisondi P, Girolomoni G. Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. Semin Thromb Hemost 2009;35:313-324.
5. Rashmi R, Rao SJ, Basavaraj KH. A comprehensive review of biomarkers in psoriasis. Clin Exp Dermatol 2009;34:658-663.
6. Yildirim M, Inaloz HS, Baysa V, Delibas N. The role of oxidants and antioxidants in psoriasis. J Eur Acad Dermatol Venereol 2003;17:34-36. (Pubitemid 36163651)
7. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figneiredo A, Quintanilha A, Teixeira F. Erythrocyte damage in mild and severe psoriasis. Br J Dermatol 2004;150:232-244. (Pubitemid 38352460)
8. Seifert O, Holmberg J, Linnarsson BM. Decreased activity of neutrophil glutathione peroxidase in chronic plaque psoriasis. J Am Acad Dermatol 2007;57:528-529. (Pubitemid 47239134)
9. Baz K, Cimen MY, Kokturk A, Yazici AC, Eskandari G, Ikizoglu G, Api H, Atik U. Oxidant/antioxidant status in patients with psoriasis. Yonsei Med J 2003;44:987-990. (Pubitemid 38081563)
10. Okayama Y. Oxidative stress in allergic and inflammatory skin diseases. Current Drug Targets-Inflamm Allergy 2005;4:517-519. (Pubitemid 41052420)
11. Zhou Q, Mrowietz U, Rostami-Yazdi M. Oxidative stress in the pathogenesis of psoriasis. Free Radic Biol Med 2009;47:891-905.
12. Korkina L, Trakhtman P, De Luca C, Leoni L, Raskovic D, Pastore S. Efficacy and safety of biologicals against immune-mediated diseases: do benefits outweigh risks? Drugs Today 2010;46:119-136.
13. Altomare G, Arcangeli F, Berardesca E, Calzavara Pinton P, Giannetti A, Girolomoni G, Lotti T, Martini P, Peserico A, Simonacci M, Vena GA. Biological drugs: differing mechanisms of action. G Ital Dermatol Venerol 2009;144:1-18.
14. Korman BD, Tyler KL, Korman NJ. Progressive multifocal leukoencephalopathy, Efalizumab and immunosuppression. Arch Dermatol 2009;145:937-942.
15. Evans R, Patzak I, Svensson L, De Filippo K, Jones K, McDowall A, Hogg N. Integrins in immunity. J Cell Sci 2009;122:215-225.
16. Van Noesel C, Miedema F, Brouwer M, De Rie MA, Aarden LA, Van Lier RAW. Regulatory properties of LFA-1 alpha and beta chains in human T-lymphocyte activation. Nature 1988;333:850-852.
17. Jullien D, Prinz JC, Langley RGB, Caro I, Dummer W, Joshi A, Dedrick K, Natta P. T-cell modulation for the treatment of chronic plaque psoriasis with Efalizumab (Raptiva™): mechanisms of action. Dermatology 2004;208:297-306. (Pubitemid 38736650)
18. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, Walicke P, Dummer W, Wang X, Garovoy MR, Pariser D. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349:2004-2013. (Pubitemid 37448923)
19. Schmits R, Kundig TM, Baker DM, Shumaker G, Simard JJ, Duncan G, Wakeham A, Shahinian A, van der Heiden A, Bachmann MF, Ohashi PS, Mak TW, Hickstein DD. LFA-1-deficient mice show normal CTL responses to virus but fail to reject immunogenic tumors. J Exp Med 1996;183:1415-1426.
20. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JYM, Elmets CA, Korman NJ, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-850. (Pubitemid 351509656)
21. Pastore S, Gubinelli E, Leoni L, Raskovic D, Korkina L. Biological drugs targeting the immune response in the therapy of psoriasis. Biologics 2008;2:687-697.
22. Frampton JE, Plosker GL. Efalizumab: a review of its use in the management of chronic moderate-to-severe plaque psoriasis. Am J Clin Dermatol 2009;10:51-72.
23. Menter A, Griffiths CE. Current and future management of psoriasis. Lancet 2007;370:272-284. (Pubitemid 47071926)
24. Werther WA, Gonzalez TN, O ' Connor SJ, McCabe S, Chan B, Hotaling T, Fox JA, Jardieu PM, Berman PW, Presta LG. Humanization of an anti-lymphocyte function-associated antigen (LFA-1) monoclonal antibody and re-engineering of the humanized antibody for binding to Rhesus LFA-1. J Immunol 1996;157:4986-4995. (Pubitemid 126449577)
25. Henseler T, Schmitt-Rau K. A comparison between BSA, PASI, PLASI and SAPASI as measures of disease severity and improvement by therapy in patients with psoriasis. Int J Dermatol 2008;47:1019-1023.
26. Brown GE, Silver GM, Reiff J, Allen RC, Fink MP. Polymorphonuclear neutrophil chemiluminescence in whole blood from blunt trauma patients with multiple injuries. J Trauma 1999;46:297-305. (Pubitemid 29102549)
27. Yagi K. A simple fluorometric assay for lipoperoxide in blood plasma. Biochem Med Metab B 1976;15:212-216.
28. Habig WH, Pabst MJ, Jakoby WB. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem 1984;249:7130-1739.
29. Aebi H. Catalase in vitro . Methods Enzymol 1974;105:121-126.
30. Paglia DE, Valentine WN. Studies on quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967;70:158-169.
31. Valacchi G, Van der Vliet A, Schock BC, Okamoto T, Obermuller-Jevic U, Cross CE, Packer L. Ozone exposure activates oxidative stress responses in murine skin. Toxicology 2002;179:163-170. (Pubitemid 35245472)
32. De Luca C, Filosa A, Grandinetti M, Maggio F, Lamba M, Passi S. Blood antioxidant status and urinary levels of catecholamine metabolites in β-thalassemia. Free Radic Res 1999;30:453-462. (Pubitemid 29326875)
33. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402-408. (Pubitemid 34164012)
34. Briganti S, Picardo M. Antioxidant activity, lipid peroxidation and skin diseases. What's new. J Eur Acad Dermatol Venereol 2003;217:663-669 (Pubitemid 37428088)
35. Deeva I, Mariani S, De Luca C, Pacifico V, Leoni L, Raskovic D, Kharaeva Z, Korkina L, Pastore S. Wide-spectrum profile of inflammatory mediators in the plasma and scales of patients with psoriatic disease. Cytokine 2010;49:63-170.
36. Schön MP. Efalizumab in the treatment of psoriasis: mode of action, clinical indications, efficacy and safety. Clinics Dermatol 2008;26:509-514.
37. Kandula S, Abraham C. LFA-1 on CD4+ T cells is required for optimal antigen-dependent activation in vivo . J Immunol 2004;173:4443-4451.
38. Steiner G, Urowitz MB. Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. Semin Arthritis Rheum 2009;38:372-381.
39. Bruch-Gerharz D, Fehsel K, Suschek C, Michel G, Ruzicka T, Kolb-Bachofen V. A proinflammatory activity of interleukin 8 in human skin: expression of the inducible nitric oxide synthase in psoriatic lesions and cultured keratinocytes. J Exp Med 1996;184:2007-2012.
40. Bruch-Gerharz D, Ruzicka T, Kolb-Bachofen V. Nitric oxide and its implications in skin homeostasis and disease - a review. Arch Dermatol Res 1998;290:643-651.
41. Kharaeva Z, Gostova E, De Luca C, Raskovic D, Korkina L. Clinical and biochemical effects of coenzyme Q10, vitamin E, and selenium supplementation to psoriasis patients. Nutrition 2009;25:295-302.
42. Korkina L, Pastore S. The role of redox regulation in the normal physiology and inflammatory diseases of the skin. Front Biosci 2009;1:123-141.
43. Bochkov VN, Oskolkova OV, Birukov KG, Levonen AL, Binder CJ, Stockl J. Generation and biological activities of oxidized phospholipids. Antioxid Redox Signal 2010;12:1009-1059.
44. Halliwell B, Chirico S. Lipid peroxidation: its mechanism, measurement, and significance. Am J Clin Nutr 1993;57:715S-724S.
45. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008;8:349-361.
46. Flohe L, Ursini F. Peroxidase: a term of many meanings. Antioxid Redox Signal 2008;10:1485-1490.
47. Alin P, Danielson UH, Mannervik B. 4-hydroxyalk-2-enals are substrates for glutathione transferase. FEBS Lett 1985;179:267-279.
48. Uchida K, Shiraishi M, Naito Y, Torii Y, Nakamura Y, Osawa TA. Activation of stress signaling pathways by the end product of lipid peroxidation. J Biol Chem 1999;274:2234-2242.
49. Zhang H, Forman HJ. Signaling pathways involved in phase II gene induction by alpha, beta-unsaturated aldehydes. Toxicol Ind Health 2009;25:269-278.
50. Kurien BT, Hensley K, Bachmann M, Scofield RH. Oxidatively modified autoantigens in autoimmune diseases. Free Radic Biol Med 2006;15:549-556.